Compare CWCO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CWCO | CBIO |
|---|---|---|
| Founded | 1973 | 2003 |
| Country | Cayman Islands | United States |
| Employees | N/A | 44 |
| Industry | Water Supply | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 471.3M |
| IPO Year | 1997 | N/A |
| Metric | CWCO | CBIO |
|---|---|---|
| Price | $29.32 | $16.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $40.00 | $26.67 |
| AVG Volume (30 Days) | 91.1K | ★ 491.9K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $132,073,368.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $42.86 | $279.20 |
| P/E Ratio | $127.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.17 | $8.72 |
| 52 Week High | $39.12 | $27.41 |
| Indicator | CWCO | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 47.36 |
| Support Level | $29.18 | $14.69 |
| Resistance Level | $30.69 | $19.13 |
| Average True Range (ATR) | 0.50 | 1.26 |
| MACD | 0.09 | 0.12 |
| Stochastic Oscillator | 77.19 | 58.82 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.